18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment Individualization

Purpose 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is utilized for staging and treatment planning of head and neck squamous cell carcinomas (HNSCC). Some older publications on the prognostic relevance showed inconclusive results, most probably due to small study sizes. This study evaluates the prognostic and potentially predictive value of FDG-PET in a large multi-center analysis. Methods Original analysis of individual FDG-PET and patient data from 16 international centers (8 institutional datasets, 8 public repositories) with 1104 patients. All patients received curative intent radiotherapy/chemoradiation (CRT) and pre-treatment FDG-PET imaging. Primary tumors were semi-automatically delineated for calculation of SUVmax, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG). Cox regression analyses were performed for event-free survival (EFS), overall survival (OS), loco-regional control (LRC) and freedom from distant metastases (FFDM). Results FDG-PET parameters were associated with patient outcome in the whole cohort regarding clinical endpoints (EFS, OS, LRC, FFDM), in uni- and multivariate Cox regression analyses. Several previously published cut-off values were successfully validated. Subgroup analyses identified tumor- and human papillomavirus (HPV) specific parameters. In HPV positive oropharynx cancer (OPC) SUVmax was well suited to identify patients with excellent LRC for organ preservation. Patients with SUVmax of 14 or less were unlikely to develop loco-regional recurrence after definitive CRT. In contrast FDG PET parameters deliver only limited prognostic information in laryngeal cancer. Conclusion FDG-PET parameters bear considerable prognostic value in HNSCC and potential predictive value in subgroups of patients, especially regarding treatment de-intensification and organ-preservation. The potential predictive value needs further validation in appropriate control groups. Further research on advanced imaging approaches including radiomics or artificial intelligence methods should implement the identified cut-off values as benchmark routine imaging parameters.

[1]  K. Fung,et al.  Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Nai-Ming Cheng,et al.  Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging , 2021, Clinical Cancer Research.

[3]  G. Landry,et al.  Distant metastasis time to event analysis with CNNs in independent head and neck cancer cohorts , 2021, Scientific Reports.

[4]  Christopher U. Jones,et al.  Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Vogelius,et al.  Multiple Testing, Cut-Point Optimization, and Signs of Publication Bias in Prognostic FDG–PET Imaging Studies of Head and Neck and Lung Cancer: A Review and Meta-Analysis , 2020, Diagnostics.

[6]  H. Amthauer,et al.  Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients , 2020, PloS one.

[7]  J. Sonke,et al.  Single-center prospective trial investigating the feasibility of serial FDG-PET guided adaptive radiotherapy for head and neck cancer. , 2020, International journal of radiation oncology, biology, physics.

[8]  H. Zeng,et al.  Evaluation of CT-based radiomics signature and nomogram as prognostic markers in patients with laryngeal squamous cell carcinoma , 2020, Cancer Imaging.

[9]  B. Ganeshan,et al.  Tumor radiomic features complement clinico-radiological factors in predicting long-term local control and laryngectomy free survival in locally advanced laryngo-pharyngeal cancers. , 2020, The British journal of radiology.

[10]  K. Fung,et al.  Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. , 2019, The Lancet. Oncology.

[11]  S. Nuyts,et al.  Faculty Opinions recommendation of Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[12]  D. Fried,et al.  Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Catalano,et al.  Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[14]  I. Steffen,et al.  Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  E. Vokes,et al.  OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Benjamin Haibe-Kains,et al.  Vulnerabilities of radiomic signature development: The need for safeguards. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  Steven J Frank,et al.  Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy , 2018, Scientific Data.

[18]  Michael Baumann,et al.  Prognostic Value of Standardized Uptake Ratio in Patients with Trimodality Treatment of Locally Advanced Esophageal Carcinoma , 2018, The Journal of Nuclear Medicine.

[19]  L. Livi,et al.  What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Vicky Goh,et al.  Challenges and Promises of PET Radiomics , 2018, International journal of radiation oncology, biology, physics.

[21]  Tom Vercauteren,et al.  Long‐term outcome of 18F‐fluorodeoxyglucose‐positron emission tomography‐guided dose painting for head and neck cancer: Matched case‐control study , 2017, Head & neck.

[22]  D. Rades,et al.  Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma , 2017, Clinical and Translational Oncology.

[23]  Issam El-Naqa,et al.  Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer , 2017, Scientific Reports.

[24]  Brian O'Sullivan,et al.  Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[25]  M. Aznar,et al.  Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  I. Apostolova,et al.  Comparative evaluation of SUV, tumor-to-blood standard uptake ratio (SUR), and dual time point measurements for assessment of the metabolic uptake rate in FDG PET , 2016, EJNMMI Research.

[27]  Andreas Wahle,et al.  DICOM for quantitative imaging biomarker development: a standards based approach to sharing clinical data and structured PET/CT analysis results in head and neck cancer research , 2016, PeerJ.

[28]  F. Hofheinz,et al.  Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma , 2015, The Journal of Nuclear Medicine.

[29]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[30]  Liane Oehme,et al.  The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG , 2013, EJNMMI Research.

[31]  Stephen M. Moore,et al.  The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository , 2013, Journal of Digital Imaging.

[32]  F Hofheinz,et al.  An automatic method for accurate volume delineation of heterogeneous tumors in PET. , 2012, Medical physics.

[33]  F Hofheinz,et al.  Automatic volume delineation in oncological PET , 2011, Nuklearmedizin.

[34]  Fréderic Duprez,et al.  Adaptive dose painting by numbers for head-and-neck cancer. , 2011, International journal of radiation oncology, biology, physics.

[35]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.